HK1052864A1 - Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy - Google Patents

Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy

Info

Publication number
HK1052864A1
HK1052864A1 HK03103784A HK03103784A HK1052864A1 HK 1052864 A1 HK1052864 A1 HK 1052864A1 HK 03103784 A HK03103784 A HK 03103784A HK 03103784 A HK03103784 A HK 03103784A HK 1052864 A1 HK1052864 A1 HK 1052864A1
Authority
HK
Hong Kong
Prior art keywords
sub
treatment
tyrosine kinase
receptor tyrosine
diabetic nephropathy
Prior art date
Application number
HK03103784A
Other languages
English (en)
Inventor
Robert Charles Atkins
Steven James Chadban
Mark Emmanuel Cooper
Richard Ernest Gilbert
Prudence Ann Hill
Darren James Kelly
Original Assignee
Novartis Ag
Univ Melbourne
Southern Health
Auatkins Robert
Steven James Chadban
Mark Emmanuel Cooper
Richard Ernest Gilbert
Prudence Ann Hill
Darren James Kelly
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Univ Melbourne, Southern Health, Auatkins Robert, Steven James Chadban, Mark Emmanuel Cooper, Richard Ernest Gilbert, Prudence Ann Hill, Darren James Kelly filed Critical Novartis Ag
Publication of HK1052864A1 publication Critical patent/HK1052864A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK03103784A 2000-03-03 2003-05-27 Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy HK1052864A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00810181 2000-03-03
PCT/EP2001/002340 WO2001064200A2 (en) 2000-03-03 2001-03-01 Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy

Publications (1)

Publication Number Publication Date
HK1052864A1 true HK1052864A1 (en) 2003-10-03

Family

ID=8174580

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03103784A HK1052864A1 (en) 2000-03-03 2003-05-27 Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy

Country Status (11)

Country Link
US (1) US7087608B2 (xx)
EP (1) EP1259242B1 (xx)
JP (1) JP2003525240A (xx)
AT (1) ATE369860T1 (xx)
AU (2) AU4832401A (xx)
CA (1) CA2401812C (xx)
DE (1) DE60129934T2 (xx)
ES (1) ES2291306T3 (xx)
HK (1) HK1052864A1 (xx)
PT (1) PT1259242E (xx)
WO (1) WO2001064200A2 (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000186A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel phenylamino-pyrimidines and uses thereof
CA2452392A1 (en) 2001-06-29 2003-01-16 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd)
WO2003002106A2 (en) 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitions for treating allergic diseases
PT1401415E (pt) 2001-06-29 2006-09-29 Ab Science Utilizacao de derivados de n-fenil-2-pirimidino-amina para o tratamento de doencas inflamatorias
EP1434991B1 (en) 2001-06-29 2007-10-17 AB Science New potent, selective and non toxic c-kit inhibitors
PL369123A1 (en) * 2001-08-25 2005-04-18 Arakis Ltd. The use of anthroquinones in the treatment of kidney disease
US7332330B2 (en) * 2001-09-11 2008-02-19 Renamed Biologics, Inc. Device for maintaining vascularization near an implant
WO2003057165A2 (en) 2002-01-04 2003-07-17 The Rockefeller University COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS
US20050261283A1 (en) * 2002-05-13 2005-11-24 Vikas Sukhatme Methods and compositions for the treatment of graft failure
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
JP4726486B2 (ja) 2002-08-02 2011-07-20 アブ サイエンス ２−（３−アミノアリール）アミノ−４−アリール−チアゾールおよびそれらのｃ−ｋｉｔ阻害薬としての使用法
GB0222514D0 (en) 2002-09-27 2002-11-06 Novartis Ag Organic compounds
KR101102229B1 (ko) * 2003-05-27 2012-01-05 닐스 리차드 웰쉬 당뇨병을 치료하기 위한 티로신 키나제 억제제의 용도
WO2005016323A2 (en) * 2003-08-15 2005-02-24 Ab Science Use of c-kit inhibitors for treating type ii diabetes
KR20170104639A (ko) 2003-11-17 2017-09-15 노파르티스 아게 디펩티딜 펩티다제 ⅳ 억제제의 용도
WO2008093246A2 (en) 2007-02-02 2008-08-07 Vegenics Limited Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis
MX353308B (es) 2008-05-21 2018-01-08 Ariad Pharma Inc Derivados fosforosos como inhibidores de cinasa.
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
SG178279A1 (en) 2009-08-05 2012-03-29 Intra Cellular Therapies Inc Novel regulatory proteins and inhibitors
CA2832504C (en) 2011-05-04 2019-10-01 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN107573322A (zh) * 2017-09-06 2018-01-12 南京优科生物医药研究有限公司 伊马替尼双氮氧化物、其制备方法和用途
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
US20220229072A1 (en) 2019-06-04 2022-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JP2602735B2 (ja) * 1989-09-27 1997-04-23 株式会社大塚製薬工場 抗活性酸素剤
TW225528B (xx) 1992-04-03 1994-06-21 Ciba Geigy Ag
JP3810020B2 (ja) 1993-04-22 2006-08-16 武田薬品工業株式会社 腎疾患の予防または治療剤
US5795910A (en) 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
US5721277A (en) 1995-04-21 1998-02-24 Sugen, Inc. Compounds and methods for inhibiting hyper-proliferative cell growth
CA2214393A1 (en) 1996-09-02 1998-03-02 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
JPH10182644A (ja) * 1996-11-01 1998-07-07 Takeda Chem Ind Ltd 三環性化合物、その製造法及び剤
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9809869D0 (en) 1998-05-09 1998-07-08 Medical Res Council Inhibition of protein kinases
PT1105136E (pt) 1998-08-13 2007-12-03 Novartis Ag Método para tratar doenças oculares neovasculares

Also Published As

Publication number Publication date
EP1259242B1 (en) 2007-08-15
CA2401812C (en) 2009-06-09
WO2001064200A3 (en) 2002-01-17
DE60129934D1 (de) 2007-09-27
ES2291306T3 (es) 2008-03-01
AU2001248324B2 (en) 2005-09-15
JP2003525240A (ja) 2003-08-26
WO2001064200A2 (en) 2001-09-07
CA2401812A1 (en) 2001-09-07
EP1259242A2 (en) 2002-11-27
US7087608B2 (en) 2006-08-08
ATE369860T1 (de) 2007-09-15
AU4832401A (en) 2001-09-12
DE60129934T2 (de) 2008-05-08
PT1259242E (pt) 2007-11-15
US20030186977A1 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
AU4832401A (en) Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
YU84603A (sh) Novi inhibitori tirozin kinaze
MXPA05010958A (es) Derivados indazol como inhibidores jnk.
NO20062136L (no) Imidazopyrazintyrosin-kinaseinhibitorer
GB0112348D0 (en) Compounds
SG151286A1 (en) 5-substituted-2-phenylamino-benzamide as mek inhibitor
ATE432259T1 (de) Pyridinderivate als dipeptedyl-peptidase-hemmer
TW515798B (en) Heterocyclic compounds for inhibition of gastric acid secretion, processes for their preparation and pharmaceutical compositions thereof
ATE253545T1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
MA32135B1 (fr) Inhibiteurs de pim kinase et leurs procedes d'utilisation
BG103964A (en) SUBSTITUTED PYRAZOLS AS p38 KINASE INHIBITORS
DE60110749D1 (de) Pyridinderivative als angiogenese- und/oder vegf-rezeptor-tyrosinkinase-inhibitoren
MY146669A (en) Pyrazole derivatives for treating hiv
NO991048L (no) Indazolderivater og deres anvendelse som inhibitorer av fosfodiesterase (PDE) type IV og fremstillingen av tumornekrosefaktor (TNF)
NO20060415L (no) Piperidyl-Kinazolinderivater som Tyrosin-Kinase-Inhibitorer
TW200508212A (en) Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
TW200616994A (en) Novel thiophene derivatives
PL1765816T3 (pl) Podstawione propiolilopiperazyny o powinowactwie do receptora MGLUR5, do leczenia stanów bólowych
DE60305514D1 (de) Neue verwendung von benzothiazolderivaten
TR200102789T2 (tr) Cns bozukluklarının tedavisi için 1-Arensülfonil-2-aril-pirolidin ve piperidin türevleri
NO963706L (no) Benzenkondenserte heterosykliske derivater og deres anvendelse
NO20034301L (no) Cyano-substituerte dihydropyrimidin forbindelser
KR20110097907A (ko) 치유적 치료를 위한 ｈｓｐ90 억제제
MXPA05012900A (es) Derivados de pirrol sustituidos.
IL161842A0 (en) 2-Amino-4-heteroarylethyl-thiazoline derivatives and their use as inhibitors of inducible no-synthase

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140301